Prostate cancer in the elderly patient

Journal of Clinical Oncology

Volumn 32, Issue 24, 2014, Pages 2523-2530

  Fung, Chunkit ^a   Dale, William ^a   Mohile, Supriya Gupta ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; CALCIUM; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; VITAMIN D;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DECISION MAKING; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HEALTH STATUS; HUMAN; LONG TERM CARE; POPULATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RADIOISOTOPE THERAPY; RADIUM THERAPY; SALVAGE THERAPY; AGE; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84906233760     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1531     Document Type: Article

References (70)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Walter LC, Covinsky KE: Cancer screening in elderly patients: A framework for individualized decision making. JAMA 285:2750-2756, 2001
3. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
4. Scosyrev E, Messing EM, Mohile S, et al: Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer 118:3062-3070, 2012
5. Dale W, Mohile SG, Eldadah BA, et al: Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst 104:581-589, 2012
6. Sajid S, Mohile SG, Szmulewitz R, et al: Individualized decision-making for older men with prostate cancer: Balancing cancer control with treatment consequences across the clinical spectrum. Semin Oncol 38:309-325, 2011
7. Dale W: "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer. J Clin Oncol 27:3420-3422, 2009
8. Koroukian SM, Murray P, Madigan E: Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 24:2304-2310, 2006
9. Mohile S, Dale W, Hurria A: Geriatric oncology research to improve clinical care. Nat Rev Clin Oncol 9:571-578, 2012
10. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005
11. Hurria A, Cohen HJ, Extermann M: Geriatric Oncology Research in the Cooperative Groups: A Report of a SIOG Special Meeting. J Geriatr Oncol 1:40-44, 2010
12. Mohile SG, Bylow K, Dale W, et al: A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109: 802-810, 2007
13. Terret C, Albrand G, Droz JP: Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2:236-240, 2004
14. Joly F, Alibhai SM, Galica J, et al: Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 176: 2443-2447, 2006
15. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
16. Newschaffer CJ, Otani K, McDonald MK, et al: Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92:613-621, 2000
17. Ketelaars L, Pottel L, Lycke M, et al: Use of the Freund clock drawing test within the Mini-Cog as a screening tool for cognitive impairment in elderly patients with or without cancer. J Geriatr Oncol 4:174-182, 2013
18. Mohile SG, Xian Y, Dale W, et al: Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst 101:1206-1215, 2009
19. Gill TM, Baker DI, Gottschalk M, et al: A prehabilitation program for physically frail community-living older persons. Arch Phys Med Rehabil 84:394-404, 2003
20. Li J, Djenaba JA, Soman A, et al: Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012:691380, 2012
21. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
22. D'Amico AV, Moul J, Carroll PR, et al: Cancerspecific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163-2172, 2003
23. Ketchandji M, Kuo YF, Shahinian VB, et al: Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 57:24-30, 2009
24. Fleming C, Wasson JH, Albertsen PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Outcomes Research Team. JAMA 269:2650-2658, 1993
25. Droz JP, Balducci L, Bolla M, et al: Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106:462-469, 2010
26. Bill-Axelson A, Holmberg L, Filén F, et al: Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 100:1144-1154, 2008
27. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012
28. Aizer AA, Paly JJ, Zietman AL, et al: Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 30:3071-3076, 2012
29. Stephenson AJ, Kattan MW, Eastham JA, et al: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300-4305, 2009
30. Alibhai SM, Naglie G, Nam R, et al: Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 21:3318-3327, 2003
31. Begg CB, Riedel ER, Bach PB, et al: Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138-1144, 2002
32. Walsh PC, DeWeese TL, Eisenberger MA: Clinical practice: Localized prostate cancer. N Engl J Med 357:2696-2705, 2007
33. Siddiqui SA, Sengupta S, Slezak JM, et al: Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 175:952-957, 2006
34. Resnick MJ, Koyama T, Fan KH, et al: Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436-445, 2013
35. Bolla M, de Reijke TM, Van Tienhoven G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516-2527, 2009
36. D'Amico AV, Chen MH, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289-295, 2008
37. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365:107-118, 2011
38. Nanda A, Chen MH, Moran BJ, et al: Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys 85:e209-e215, 2013
39. Brachman DG, Thomas T, Hilbe J, et al: Failurefree survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48:111-117, 2000
40. Studer UE, Whelan P, Wimpissinger F, et al: Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: Final results of EORTC Randomized Trial 30891 with 12 years of follow-up. Eur Urol 10.1016/j.eururo.2013.07.024 [epub ahead of print on July 24, 2013]
41. Johansson E, Steineck G, Holmberg L, et al: Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: The Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 12:891-899, 2011
42. Antonarakis ES, Feng Z, Trock BJ, et al: The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up. BJU Int 109:32-39, 2012
43. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659, 1994
44. Valicenti RK, Thompson I Jr, Albertsen P, et al: Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/ American Urological Association guidelines. Int J Radiat Oncol Biol Phys 86:822-828, 2013
45. Trock BJ, Han M, Freedland SJ, et al: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760-2769, 2008
46. Cotter SE, Chen MH, Moul JW, et al: Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 117:3925-3932, 2011
47. Ryan CJ, Small EJ: Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 23:8225-8231, 2005
48. Dale W, Hemmerich J, Bylow K, et al: Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: A prospective cohort study. J Clin Oncol 27:1557-1563, 2009
49. Paller CJ, Antonarakis ES: Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin Adv Hematol Oncol 11:14-23, 2013
50. Calais da Silva FE, Bono AV, Whelan P, et al: Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol 55:1269-1277, 2009
51. Crook JM, O'Callaghan CJ, Duncan G, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
52. Mohile SG, Mustian K, Bylow K, et al: Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol 70:235-255, 2009
53. Bylow K, Dale W, Mustian K, et al: Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 72:422-427, 2008
54. Alibhai SM, Breunis H, Timilshina N, et al: Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 28:5038-5045, 2010
55. Alibhai SM, Breunis H, Timilshina N, et al: Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 28:5030-5037, 2010
56. Smith MR, Egerdie B, Hernández Toriz N, et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer.NEngl JMed 361:745-755, 2009
57. Monk JP, Halabi S, Picus J, et al: Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782. Cancer 118:4139-4147, 2012
58. Viani GA, Bernardes da Silva LG, Stefano EJ: Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: Tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys 83:e519-e524, 2012
59. Hussain M, Tangen CM, Berry DL, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-1325, 2013
60. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
61. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
62. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 376:1147-1154, 2010
63. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
64. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
65. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
66. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
67. Italiano A, Ortholan C, Oudard S, et al: Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 55:1368-1375, 2009
68. Mulders PF, Molina A, Marberger M, et al: Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxelbased chemotherapy. Eur Urol 65:875-883, 2014
69. Sternberg CN, De Bono JS, Chi KN, et al: Outcomes in elderly patients with metastatic castrationresistant prostate cancer (mCRPC) treated with the androgen receptor inhibior enzalutamide: Results from the phase III AFFIRM trial. 2013 ASCO Genitourinary Cancers Symposium, Orlando, FL, February 14-16, 2013. J Clin Oncol 31, 2013 (suppl 6; abstr 16)
70. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377:813-822, 2011